Publications
Detailed Information
Immunophenotypic landscape and prognosis of diffuse large B-cell lymphoma with MYC/BCL2 double expression: An analysis of a prospectively immunoprofiled cohort
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Han, Bogyeong | - |
dc.contributor.author | Kim, Sehui | - |
dc.contributor.author | Koh, Jiwon | - |
dc.contributor.author | Yim, Jeemin | - |
dc.contributor.author | Lee, Cheol | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.contributor.author | Kim, Tae Min | - |
dc.contributor.author | Paik, Jin Ho | - |
dc.contributor.author | Jeon, Yoon Kyung | - |
dc.date.accessioned | 2023-05-08T00:33:36Z | - |
dc.date.available | 2023-05-08T00:33:36Z | - |
dc.date.created | 2020-12-14 | - |
dc.date.created | 2020-12-14 | - |
dc.date.created | 2020-12-14 | - |
dc.date.issued | 2020-11 | - |
dc.identifier.citation | Cancers, Vol.12 No.11, pp.3305-15 | - |
dc.identifier.issn | 2072-6694 | - |
dc.identifier.uri | https://hdl.handle.net/10371/191882 | - |
dc.description.abstract | Simple Summary Diffuse large B-cell lymphoma (DLBCL) with MYC/BCL2 double-expression (DE), a recently proposed poor prognostic group, can be easily identified by immunohistochemistry in routine clinical practice. However, clinical outcomes of DE-DLBCL patients vary immensely after R-CHOP immunochemotherapy and prognostic impact of MYC/BCL2-DE was conflicting according to the cell-of-origin, i.e., between germinal center-B-cell (GCB)- and non-GCB-DLBCLs. This implies the heterogeneity within DE-DLBCLs and emphasizes a need for proper risk stratification to select the patients who require more intensive therapy. By analyzing a prospectively immunoprofiled cohort of consecutively diagnosed DLBCL patients, we confirmed the poor prognostic value of MYC/BCL2-DE in DLBCL patients treated with R-CHOP irrespective of the cell-of-origin and international prognostic index. DE-DLBCLs with a concurrent risk factor, especially, elevated serum lactate dehydrogenase (LDH), had the worst survival and DE-DLBCL patients with normal LDH had clinical outcomes similar to those of non-DE-DLBCL patients. Risk stratification of DE-DLBCL based on serum LDH may guide clinical decision-making for DE-DLBCL patients. Diffuse large B-cell lymphoma (DLBCL) patients with MYC/BCL2 double expression (DE) show poor prognosis and their clinical outcomes after R-CHOP therapy vary immensely. We investigated the prognostic value of DE in aggressive B-cell lymphoma patients (n = 461), including those with DLBCL (n = 417) and high-grade B-cell lymphoma (HGBL; n = 44), in a prospectively immunoprofiled cohort. DE was observed in 27.8% of DLBCLs and 43.2% of HGBLs (p = 0.058). DE-DLBCL patients were older (p = 0.040) and more frequently exhibited elevated serum LDH levels (p = 0.002), higher international prognostic index (IPI; p = 0.042), non-germinal-center B-cell phenotype (p < 0.001), and poor response to therapy (p = 0.042) compared to non-DE-DLBCL patients. In R-CHOP-treated DLBCL patients, DE status predicted poor PFS and OS independently of IPI (p < 0.001 for both). Additionally, in DE-DLBCL patients, older age (>60 years; p = 0.017), involvement of >= 2 extranodal sites (p = 0.021), bone marrow involvement (p = 0.001), high IPI (p = 0.017), CD10 expression (p = 0.006), poor performance status (p = 0.028), and elevated LDH levels (p < 0.001) were significantly associated with poor OS. Notably, DE-DLBCL patients with normal LDH levels exhibited similar PFS and OS to those of patients with non-DE-DLBCL. Our findings suggest that MYC/BCL2 DE predicts poor prognosis in DLBCL. Risk stratification of DE-DLBCL patients based on LDH levels may guide clinical decision-making for DE-DLBCL patients. | - |
dc.language | 영어 | - |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | - |
dc.title | Immunophenotypic landscape and prognosis of diffuse large B-cell lymphoma with MYC/BCL2 double expression: An analysis of a prospectively immunoprofiled cohort | - |
dc.type | Article | - |
dc.identifier.doi | 10.3390/cancers12113305 | - |
dc.citation.journaltitle | Cancers | - |
dc.identifier.wosid | 000593600800001 | - |
dc.identifier.scopusid | 2-s2.0-85096649000 | - |
dc.citation.endpage | 15 | - |
dc.citation.number | 11 | - |
dc.citation.startpage | 3305 | - |
dc.citation.volume | 12 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Heo, Dae Seog | - |
dc.contributor.affiliatedAuthor | Paik, Jin Ho | - |
dc.contributor.affiliatedAuthor | Jeon, Yoon Kyung | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | RITUXIMAB PLUS CYCLOPHOSPHAMIDE | - |
dc.subject.keywordPlus | BURKITT-LYMPHOMA | - |
dc.subject.keywordPlus | GENE-EXPRESSION | - |
dc.subject.keywordPlus | OF-ORIGIN | - |
dc.subject.keywordPlus | MYC | - |
dc.subject.keywordPlus | BCL2 | - |
dc.subject.keywordPlus | CLASSIFICATION | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | FEATURES | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordAuthor | diffuse large B-cell lymphoma | - |
dc.subject.keywordAuthor | high-grade B-cell lymphoma | - |
dc.subject.keywordAuthor | MYC | - |
dc.subject.keywordAuthor | BCL2 | - |
dc.subject.keywordAuthor | double expression | - |
dc.subject.keywordAuthor | prognosis | - |
dc.subject.keywordAuthor | lactate dehydrogenase | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.